蒽环类治疗后T-DM1联合帕妥珠单抗对比紫杉类联合曲妥珠单抗联合帕妥珠单抗治疗高危HER2阳性早期乳腺癌:III期KAITLIN研究
KAITLIN研究纳入术后高危HER2阳性早期乳腺癌患者,随机接受蒽环类后T-DM1联合帕妥珠单抗(AC-KP)或紫杉类联合曲妥珠单抗联合帕妥珠单抗(AC-THP)。主要终点未达到:两组无浸润性疾病生存(IDFS)无显著差异。曲妥珠单抗联合帕妥珠单抗加化疗仍是高危HER2阳性早期乳腺癌的标准治疗。
要点
- AC-KP与AC-THP在淋巴结阳性及总体人群中IDFS均无显著差异。
- AC-KP组治疗完成率65.0%低于AC-THP组88.4%,差异源于T-DM1因实验室异常停药(12.5%)。
- 两组≥3级不良事件(55.4% vs 51.8%)和严重不良事件(23.3% vs 21.4%)发生率相似。
核心结论
- 主要终点未达到,AC-KP与AC-THP在淋巴结阳性及总体人群中IDFS无显著差异,两臂均获得良好IDFS。
研究设计与样本
- III期KAITLIN研究(NCT01966471)纳入已切除的HER2阳性早期乳腺癌成人患者(淋巴结阳性,或淋巴结阴性且激素受体阴性且肿瘤>2.0 cm)。
- 术后患者按1:1随机分配至蒽环类化疗(3-4周期)后18周期T-DM1联合帕妥珠单抗(AC-KP),或紫杉类(3-4周期)联合曲妥珠单抗联合帕妥珠单抗(AC-THP);允许辅助放疗/内分泌治疗。
- 共同主要终点为意向治疗淋巴结阳性人群和总体人群的浸润性疾病生存(IDFS),采用序贯检验。
主要发现
- AC-THP组中位随访57.1个月(四分位距52.1-60.1个月,n=918),AC-KP组57.0个月(四分位距52.1-59.8个月,n=928)。
- 淋巴结阳性人群(n=1658)IDFS分层HR 0.97(95%CI 0.71-1.32),总体人群(n=1846)分层HR 0.98(95%CI 0.72-1.32),均无显著差异。
- 总体人群中3年IDFS:AC-THP组94.2%(95%CI 92.7-95.8),AC-KP组93.1%(95%CI 91.4-94.7)。
- 完成18周期治疗的患者比例:AC-THP组88.4%,AC-KP组65.0%,差异源于T-DM1因实验室异常停药(12.5%)。
- ≥3级不良事件发生率AC-THP组55.4% vs AC-KP组51.8%,严重不良事件23.3% vs 21.4%。
关键数值与推荐
- AC-KP与AC-THP在淋巴结阳性人群IDFS分层HR 0.97(95%CI 0.71-1.32),总体人群分层HR 0.98(95%CI 0.72-1.32)。
- 3年IDFS:AC-THP组94.2%(95%CI 92.7-95.8),AC-KP组93.1%(95%CI 91.4-94.7)。
- 完成18周期治疗率:AC-THP组88.4%,AC-KP组65.0%;T-DM1因实验室异常停药率12.5%。
- ≥3级不良事件:AC-THP组55.4%,AC-KP组51.8%;严重不良事件:AC-THP组23.3%,AC-KP组21.4%。
- 总体健康状况临床有意义恶化:KP对比THP分层HR 0.71(95%CI 0.62-0.80)。
临床怎么用
- 曲妥珠单抗联合帕妥珠单抗加化疗仍是高危HER2阳性早期乳腺癌的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS: The phase III KAITLIN study (NCT01966471) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor-negative, and tumor > 2.0 cm). Postsurgery, patients were randomly assigned 1:1 to anthracycline-based chemotherapy (three-four cycles) and then 18 cycles of T-DM1 plus pertuzumab (AC-KP) or taxane (three-four cycles) plus trastuzumab plus pertuzumab (AC-THP). Adjuvant radiotherapy/endocrine therapy was permitted. Coprimary end points were invasive disease-free survival (IDFS) in the intention-to-treat node-positive and overall populations with hierarchical testing. RESULTS: The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) for AC-THP (n = 918) and 57.0 months (interquartile range, 52.1-59.8 months) for AC-KP (n = 928). There was no significant IDFS difference between arms in the node-positive (n = 1,658; stratified hazard ratio [HR], 0.97; 95% CI, 0.71 to 1.32) or overall population (n = 1846; stratified HR, 0.98; 95% CI, 0.72 to 1.32). In the overall population, the three-year IDFS was 94.2% (95% CI, 92.7 to 95.8) for AC-THP and 93.1% (95% CI, 91.4 to 94.7) for AC-KP. Treatment completion rates (ie, 18 cycles) were 88.4% for AC-THP and 65.0% for AC-KP (difference driven by T-DM1 discontinuation because of laboratory abnormalities [12.5%]). Similar rates of grade ≥ 3 (55.4% v 51.8%) and serious adverse events (23.3% v 21.4%) occurred with AC-THP and AC-KP, respectively. KP decreased clinically meaningful deterioration in global health status versus THP (stratified HR, 0.71; 95% CI, 0.62 to 0.80). CONCLUSION: The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
引用
- Krop IE, Im SA, Barrios C, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. J Clin Oncol. 2021. PMID: 34890214. doi:10.1200/JCO.21.00896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。